Active agent for regeneration of the lung
TransMIT Gesellschaft für Technologietransfer mbH
Medicamentous regeneration of forms of lung damage as a result of chronic lung diseases such as COPD, pulmonary fibrosis, asthma etc. is possible for the first time thanks to the new active agent.
The novel active agent may remove the necessity of having to undergo a risky lung transplantation and could cure the disease, making it of interest to a broad patient population.
Product description and business case
By applying a known substance in a new manner it is possible to treat severe lung damage resulting from chronic lung diseases medicamentously for the first time, thereby potentially preventing the need for a lung transplantation or even the death of the patient. The lung structure can be rebuilt and its function can therefore be restored.
The novel active agent is of interest to pharmaceutical companies which develop and synthesize drugs and perform clinical studies for patients with lung diseases such as chronic obstructive pulmonary disease (COPD), tuberculosis, pulmonary emphysema, lung and bronchial carcinoma, and pulmonary fibrosis.
Market, fields of application, and market tendencies (US, EU, Asia)
A significant increase in the number of fatalities as a result of lung diseases is predicted to occur by the year 2020, especially for chronic obstructive lung disease (COPD), lung cancer, and tuberculosis (TB). In 2020, 11.9 million fatalities will be caused by lung diseases worldwide (4.9 million by COPD, 2.5 million by pneumonia, 2.4 million by TB, and 2.3 million by lung cancer). Globally, lung diseases come second in terms of mortality, incidence, prevalence, and costs (cardiovascular diseases come first); in some countries (e.g. Great Britain) they are already the leading killer. Around 44 million patients worldwide are estimated to suffer from COPD alone. The frequency of a clinically relevant COPD varies between 4 and 10% among the adult population of countries in Europe. Between 200,000 and 300,000 people die annually in Europe due to COPD. The total cost involved in the treatment of lung diseases in Europe amounts to nearly 102 billion euro. COPD accounts for around half of this amount, followed by asthma, pneumonia, lung cancer, and tuberculosis (Source: European Lung Foundation).
Unique selling proposition (USP)
To date, severe lung damage as a result of diseases such as COPD can neither be cured, nor can the progression of the disease be completely delayed. The current treatment only tends to slow down the deterioration of the disease and/or decrease discomfort. As such, medicaments such as bronchodilator drugs, inhaled corticosteroids, supply of oxygen, and other medicamentous drugs including antibiotics for bacterial infections of the respiratory tract, mucolytics, and antioxidants are applied.The new application of the known substance is beneficial for the regeneration of lung structure and restoration of the lung function, thereby ensuring that a curative therapy for lung diseases that cause lung damage is available for the first time.
Status quo of the product development
The invention was tested in vivo in experiments with mice. After exposure to smoke, these mice showed regeneration of the lung, including reconstruction of structure and restoration of function, when the novel active agent was applied. The results suggest that the active substance is applicable as an agent for prophylaxis and/or treatment of chronic lung diseases or for regeneration of the lung.
A European patent application was filed on 9 July 2010 at the European Patent Office. An international PCT application is planned. The content of the application is still confidential until January 2012. Access to the application’s content will nevertheless be granted once a confidentiality agreement is signed.
Options for cooperation
TransMIT GmbH is searching for partners for further development, preclinical and clinical proofs of the active agent up to routine application in Europe, US, and Asia.
Invitation for discussion with experts and market analysts
After signing of a CDA the possibility for a dialogue with experts/scientists, market analysts, and innovation managers will be given in order to provide a deeper insight into the new technology.